Wanbury Ltd

Wanbury Ltd Share Price Today: Live Updates & Key Insights

Get insights on Wanbury Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Wanbury Ltd Share Price Chart

Wanbury Ltd Fundamentals

Traded Volume: 73,055

Market Cap(Cr): 863

Avg Traded Price 69.06

1 Year return 1.32%

Upper Circuit 256.9

Lower Circuit 240.1

P/E TTM 19.00

P/B Ratio 13.00

Traded Value(Cr) 180.67

EPS TTM 13.116

Book value 13.116

Dividend 0.00%

Wanbury Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Wanbury Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Wanbury Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -3.94%

1M -3.49%

3M -3.02%

1Y +1.32%

YTD -14.40%

Wanbury Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Wanbury Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 63161.00

Day Before Yesterday 1.30L

1W Avg 1.26L

1M Avg 1.21L

3M Avg 1.01L

Wanbury Ltd Technical Details

Wanbury Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 239

Support 2 231

Support 3 222

Pivot Point : 248

Resistance 1 256

Resistance 2 265

Resistance 3 273

Wanbury Ltd Corporate Actions

Wanbury Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Wanbury Ltd’s capital allocation strategies.

All

Ex-Date 29-Jul-2010 Type D Description 1.00/share@10.00% Record Date 07-Nov-2025 Ratio 10.00

Ex-Date 12-Mar-2009 Type D Description 0.50/share@5.00% Record Date 07-Nov-2025 Ratio 5.00

Ex-Date 13-Sep-2007 Type D Description 2.00/share@20.00% Record Date 07-Nov-2025 Ratio 20.00

Dividends

Announcement Date 29-Jul-2010 Ex Dividend Date 29-Jul-2010 Dividend(%) 10

Announcement Date 12-Mar-2009 Ex Dividend Date 12-Mar-2009 Dividend(%) 5

Announcement Date 13-Sep-2007 Ex Dividend Date 13-Sep-2007 Dividend(%) 20

Bonus

No Bonus has been declared by WANBURY

Splits

No Split has been declared by WANBURY

Others

Rights No Rights has been declared by WANBURY

Wanbury Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Wanbury Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Wanbury Ltd's relative performance and valuation against major competitors.

Stock Name Fermenta Biotech Ltd ₹281.00 (+1.70%) M. Cap (Cr) 8.27 1 Yr Return (%) -16.80% P/E (TTM) 7.85 PB Ratio 2.82

Stock Name Bharat Parenterals Ltd ₹1195.00 (-0.42%) M. Cap (Cr) 8.24 1 Yr Return (%) -20.41% P/E (TTM) -52.46 PB Ratio 2.49

Stock Name Ind-Swift Laboratories Ltd ₹100.60 (-0.47%) M. Cap (Cr) 7.39 1 Yr Return (%) -11.75% P/E (TTM) 3.55 PB Ratio 0.79

Stock Name Wanbury Ltd ₹247.30 (-2.47%) M. Cap (Cr) 8.63 1 Yr Return (%) +1.32% P/E (TTM) 18.85 PB Ratio 20.91

Stock Name Kopran Ltd ₹158.46 (-1.22%) M. Cap (Cr) 7.65 1 Yr Return (%) -50.47% P/E (TTM) 21.92 PB Ratio 1.48

Stock Name Anlon Healthcare Ltd ₹139.16 (-0.38%) M. Cap (Cr) 7.40 1 Yr Return (%) NaN% P/E (TTM) PB Ratio 7.89

Stock Name Fredun Pharmaceuticals Ltd ₹1564.00 (+1.01%) M. Cap (Cr) 7.38 1 Yr Return (%) +117.62% P/E (TTM) 31.24 PB Ratio 5.60

Wanbury Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Wanbury Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 26.10 Mar 2024 4.02 Mar 2023 19.80 Mar 2022 40.52 Mar 2021 16.68

PARTICULARS Investing Activities Mar 2025 -51.17 Mar 2024 -16.63 Mar 2023 -8.84 Mar 2022 0.59 Mar 2021 8.04

PARTICULARS Financing Activities Mar 2025 25.73 Mar 2024 14.55 Mar 2023 -31.99 Mar 2022 -28.58 Mar 2021 -17.39

PARTICULARS Net Cash Flow Mar 2025 0.66 Mar 2024 1.94 Mar 2023 -21.03 Mar 2022 12.52 Mar 2021 7.34

Wanbury Ltd Shareholding Pattern

This shows the ownership breakdown of Wanbury Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 39.63%

Public 59.55%

Other Institutions 0.0%

FII 0.8%

Mutual Funds null%

About Wanbury Ltd

Wanbury Ltd (Formerly known Pearl Organics Limited) was incorporated in August, 1988. The Company is engaged in the business of pharmaceutical and related activities, including research. The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs. In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga. In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US. In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007. Pursuant to the aforesaid Order of the Hon`ble Bl FR 7,85,557 Equity Shares of face value of Rs. 10/- each of the Company were issued to the Equity Shareholders of DOCL on 17th March, 2008. Similarly, the Pharmaceutical Products of India Limited (PPIL) was merged with the Company effective from April 1, 2006. In terms of the said Scheme of Merger, the Company had issued 5,62,618 Equity Shares of face value of Rs. 10/- each to the Equity Shareholders of PPIL on 27 June, 2007, which got listed on Bombay Stock Exchange Limited and National Stock Exchange Limited respectively. The company entered into a strategic association with Bravo Healthcare Ltd and incorporated Ningxia Wanbury Fine Chemicals Co Ltd to source raw materials from China. It opened its office in Zurich,Switzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008. The novel product `Cdense Gems` was launched in May, 2008. The Company completed the restructuring of the Formulation Division during the year 2013. It launched, Myotol-F, targeted at female infertility in 2013, it launched Folinine. The Company`s newly launched products Myotol-F (to treat polycystic ovarian syndrome) and Cal-K2 (in prevention and management of Osteoporosis) were labelled as one of the best launches in 2014.

E D & Wholetime Director

K Chandran

Registered office BSEL Tech Park B-Wing 10th Flr, Sector 30 A Opp Vashi Rly Stat, Navi Mumbai, Maharashtra, 400703

FAX :91-22-67942222

Background

Incorporation Year 1988

Face Value ₹10.00

Market Lot 1

Wanbury Ltd Latest News

VIEW MORE NEWS

FAQs on Wanbury Ltd